113 related articles for article (PubMed ID: 16165353)
1. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
Mai A; Massa S; Rotili D; Pezzi R; Bottoni P; Scatena R; Meraner J; Brosch G
Bioorg Med Chem Lett; 2005 Nov; 15(21):4656-61. PubMed ID: 16165353
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
Mai A; Massa S; Rotili D; Simeoni S; Ragno R; Botta G; Nebbioso A; Miceli M; Altucci L; Brosch G
J Med Chem; 2006 Oct; 49(20):6046-56. PubMed ID: 17004718
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
4. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
6. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
7. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Dallavalle S; Cincinelli R; Nannei R; Merlini L; Morini G; Penco S; Pisano C; Vesci L; Barbarino M; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2009 May; 44(5):1900-12. PubMed ID: 19084294
[TBL] [Abstract][Full Text] [Related]
10. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
11. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
12. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
Mai A; Perrone A; Nebbioso A; Rotili D; Valente S; Tardugno M; Massa S; De Bellis F; Altucci L
Bioorg Med Chem Lett; 2008 Apr; 18(8):2530-5. PubMed ID: 18381238
[TBL] [Abstract][Full Text] [Related]
13. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
14. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
15. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
16. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
[TBL] [Abstract][Full Text] [Related]
19. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
20. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]